Unicycive Therapeutics, Inc., (UNCY) News
Filter UNCY News Items
UNCY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
UNCY News Highlights
- UNCY's 30 day story count now stands at 2.
- Over the past 19 days, the trend for UNCY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about UNCY are ARM, DEC and NOV.
Latest UNCY News From Around the Web
Below are the latest news stories about UNICYCIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate UNCY as an investment opportunity.
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on DialysisStudy will Evaluate 60 Participants with Results Expected in Q2 2024LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC). OLC is a next-generation lanthanum-based phosp |
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023. Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)Presentation: Monday, December 4, 2023 at 3:30 pm ET Boca Rat |
Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022)Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net loss: US$4.41m (loss... |
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business UpdateReached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a bus |
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the path forward for Oxylanthanum Carbonate (OLC) and on the overall package requirements to file a New Drug App |
The 7 Most Undervalued Penny Stocks to Buy in October 2023Undervalued penny stocks offer tremendous return for investors with an appetite for risk but these shares are relatively safe as well. |
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhDAppointment adds decades of drug development experience from a seasoned executive Sara Kenkare-Mitra, PhD Sara Kenkare-Mitra, PhD LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company’s Board of Directors, effective September 6, 2023. As a veteran of the b |
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight SeriesLOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer was recently featured on the Nasdaq Amplify Issuer Spotlight interview series. The series explores how industry leaders within small-cap community are evolving and navigating challenges in various industries. A l |
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business UpdateRecent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA Expected in Fall 2023 for OLC Program UNI-494 Phase 1 Trial Progressing as Planned with IND Application Expected in 2024 LOS ALTOS, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies |